The final FY 2026 National Defense Authorization Act (NDAA) was released on December 7, inclusive of a modified version of the Senate-passed BIOSECURE Act from October. This final bill maintains the ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies. The ...

After months of sharp share-price declines, WuXi AppTec and WuXi Biologics enjoyed a brief respite Wednesday amid new uncertainties about the legislative path of the BIOSECURE Act. WuXi AppTec and ...

After a year in the shadows, the controversial BIOSECURE Act could make a return following an endorsement of a revised iteration by both chambers of Congress. The bipartisan amendment, submitted by ...

The regulatory landscape across the Asia-Pacific (APAC) region is evolving rapidly, and pharmaceutical companies must adapt to maintain compliance, mitigate risk, and seize new opportunities. To ...

After years in legislative limbo, the BIOSECURE Act – albeit with a softer framework – is poised to enter the home stretch on Capitol Hill before being enacted into US law. Congress released the final ...

As a scientist, I’ve devoted my career to advancing genomic sequencing to help us better understand diseases that impact us all. Genomic sequencing is a major driver of prevention, diagnosis, ...

The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

A collage shows the US Capitol building with some drug packets and a strand of DNA behind the building. The Biosecure Act, which aims to dissociate the US pharmaceutical industry from a handful of ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The approved version of the Biosecure Act is slimmer than ...

With the specter of the BIOSECURE Act clouding its future, China’s WuXi AppTec sustained its fourth straight period with a year-over-year revenue decline as the contract research, development and ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...